Pipeline — registered trials by phase
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
— · Medullary Thyroid Cancer · Active Not Recruiting · est. 2020-07-15
A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function
— · Healthy, Renal Impairment · Completed · est. 2013-04
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
— · Non Small Cell Lung Cancer, Cervical Cancer, SCCHN · Completed · est. 2025-03-10
Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
— · Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma · Completed · est. 2012-11
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
— · Solid Tumors · Recruiting · est. 2027-11
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
— · Cancer, Pediatric Cancer · Not Yet Recruiting · est. 2028-07-31
A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
— · Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer · Completed · est. 2012-08
Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects
— · Healthy, Hepatic Impairment · Completed · est. 2014-05
Study of XL281 in Adults With Solid Tumors
— · Cancer, Non-small-cell Lung Cancer, Colorectal Cancer · Completed · est. 2011-10
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
— · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC) · Recruiting · est. 2027-01-31
Study of XB010 in Subjects With Solid Tumors
— · Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer · Recruiting · est. 2026-11-23
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
— · Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma · Active Not Recruiting · est. 2026-08-31
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
— · Lymphoma, Cancer, Thyroid Carcinoma · Completed · est. 2011-04
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
— · Solid Tumors, Cancer, NSCLC · Completed · est. 2015-05
Study of XL820 in Adults With Solid Tumors
— · Cancer · Completed
Study of XL820 Given Orally Daily to Subjects With Solid Tumors
— · Cancer · Completed
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
— · Hepatic Impairment, Moderate Hepatic Impairment · Recruiting · est. 2025-12
Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
— · Glioblastoma Multiforme · Completed · est. 2012-06
A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)
— · Carcinoma, Non-Small-Cell Lung · Completed · est. 2012-08-02
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
— · Meningioma · Recruiting · est. 2028-02-29
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
— · Squamous Non-Small Cell Lung Cancer (NSCLC) · Not Yet Recruiting · est. 2028-06-15
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
— · Hepatocellular Carcinoma · Completed · est. 2017-10-16
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
— · Head and Neck Squamous Cell Carcinoma · Active Not Recruiting · est. 2028-08
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
— · Hepatocellular Carcinoma · Active Not Recruiting · est. 2021-11-30
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
— · Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) · Recruiting · est. 2029-06-30
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
— · Differentiated Thyroid Cancer · Active Not Recruiting · est. 2020-08-19
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
— · Renal Cell Carcinoma · Active Not Recruiting · est. 2022-01-31
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
— · Metastatic Prostate Cancer, Prostate Adenocarcinoma · Active Not Recruiting · est. 2024-04-19
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
— · Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET) · Enrolling By Invitation · est. 2030-05-31
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
— · Thyroid Cancer · Completed · est. 2011-10
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
— · Colorectal Cancer · Recruiting · est. 2030-04-05
CometriqCabozantinib S-Malate
Source: ClinicalTrials.gov (trials where Exelixis is lead sponsor; 31 active or completed) and Drugs@FDA (1 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-11Current report (material event)
- 8-K2026-08-31Current report (material event)
- SCHEDULE 13D/A2026-08-14SCHEDULE 13D/A
- SCHEDULE 13G/A2026-08-12SCHEDULE 13G/A
- S-82026-08-05Employee stock plan
- 10-Q2026-08-05Quarterly report
- 8-K2026-08-05Current report (material event)
- 8-K2026-05-29Current report (material event)
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- DEFA14A2026-04-17DEFA14A
- DEFA14A2026-04-15DEFA14A
- DEF 14A2026-04-15Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- SCHEDULE 13G2026-02-13SCHEDULE 13G
- 10-K2026-02-10Annual report
- 8-K2026-02-10Current report (material event)
- 8-K2026-01-12Current report (material event)
- SCHEDULE 13D/A2026-01-05SCHEDULE 13D/A
- 8-K2025-11-07Current report (material event)
- 10-Q2025-11-04Quarterly report
- 8-K2025-11-04Current report (material event)
- 8-K2025-08-29Current report (material event)
- 10-Q2025-07-28Quarterly report
- 8-K2025-07-28Current report (material event)
- 8-K2025-06-02Current report (material event)
- SCHEDULE 13D/A2025-05-20SCHEDULE 13D/A
- 10-Q2025-05-13Quarterly report
- 8-K2025-05-13Current report (material event)
- SCHEDULE 13G/A2025-04-28SCHEDULE 13G/A
- ARS2025-04-16Annual report to holders
- DEFA14A2025-04-16DEFA14A
- DEF 14A2025-04-16Proxy statement
- 8-K2025-03-31Current report (material event)
- SCHEDULE 13D/A2025-03-05SCHEDULE 13D/A
- 8-K2025-02-21Current report (material event)
- 10-K2025-02-11Annual report
- 8-K2025-02-11Current report (material event)
- 8-K2025-01-13Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.